Success Metrics

Completion Rate
0%(0/2)
Active Trials
5(50%)
Terminated
2(20%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_3
1
10%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Terminated(2)
Other(3)

Detailed Status

Recruiting3
unknown3
Terminated2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 25 (62.5%)
Phase 31 (12.5%)

Trials by Status

terminated220%
recruiting330%
unknown330%
active_not_recruiting220%

Recent Activity

5 active trials
Showing 5 of 10
active_not_recruitingphase_2

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398
active_not_recruitingphase_2

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938
recruitingphase_3

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

NCT05236946
recruitingphase_2

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

NCT04440267
recruiting

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

NCT03958565
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03817398Phase 2

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Active Not Recruiting
NCT04318938Phase 2

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Active Not Recruiting
NCT05236946Phase 3

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Recruiting
NCT04440267Phase 2

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting
NCT03958565

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting
NCT02949843Phase 2

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Terminated
NCT06121765

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Unknown
NCT04006847Phase 1

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Terminated
NCT04760431Phase 2

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Unknown
NCT03799094Phase 1

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10